Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating
TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793
Eli Lilly and Co Analyst Ratings
Eli Lilly & Co (LLY) Gets a Buy From Barclays
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating
Berenberg Maintains Buy on Eli Lilly and Co, Raises Price Target to $1000
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating
Eli Lilly and Co Analyst Ratings
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly and Co Analyst Ratings
Goldman Sachs Adjusts Price Target on Eli Lilly & Co. to $793 From $785, Maintains Neutral Rating
Eli Lilly and Co Analyst Ratings
Eli Lilly and Co Analyst Ratings
Truist Securities Reiterates Buy on Eli Lilly and Co, Raises Price Target to $1000
Eli Lilly and Co Analyst Ratings
Jefferies Adjusts Price Target on Eli Lilly to $1,015 From $994
Eli Lilly and Co Analyst Ratings
Eli Lilly and Co Analyst Ratings